Citadel Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-155,800
| Closed | -$6.27M | – | 13638 |
|
|
2026
Q1 | $6.27M | Buy |
155,800
+15,600
| +11% | +$336K | ﹤0.01% | 3979 |
|
|
2025
Q4 | $3.52M | Sell |
140,200
-7,700
| -5% | -$181K | ﹤0.01% | 4875 |
|
|
2025
Q3 | $3.35M | Buy |
147,900
+35,100
| +31% | +$819K | ﹤0.01% | 5102 |
|
|
2025
Q2 | $1.95M | Buy |
112,800
+600
| +0.5% | +$11.1K | ﹤0.01% | 5745 |
|
|
2025
Q1 | $2.45M | Sell |
112,200
-22,100
| -16% | -$611K | ﹤0.01% | 5141 |
|
|
2024
Q4 | $4.29M | Sell |
134,300
-9,600
| -7% | -$289K | ﹤0.01% | 4212 |
|
|
2024
Q3 | $4.15M | Sell |
143,900
-74,400
| -34% | -$2.76M | ﹤0.01% | 4258 |
|
|
2024
Q2 | $8.37M | Buy |
218,300
+80,900
| +59% | +$3.66M | ﹤0.01% | 3012 |
|
|
2024
Q1 | $8.08M | Sell |
137,400
-257,500
| -65% | -$16.4M | ﹤0.01% | 3223 |
|
|
2023
Q4 | $23.6M | Sell |
394,900
-285,000
| -42% | -$14.5M | ﹤0.01% | 1849 |
|
|
2023
Q3 | $25.9M | Buy |
679,900
+549,300
| +421% | +$24.1M | 0.01% | 1619 |
|
|
2023
Q2 | $11.9M | Sell |
130,600
-87,900
| -40% | -$7.58M | ﹤0.01% | 2452 |
|
|
2023
Q1 | $14.4M | Sell |
218,500
-70,700
| -24% | -$4.08M | ﹤0.01% | 2320 |
|
|
2022
Q4 | $15M | Buy |
289,200
+84,900
| +42% | +$4.5M | ﹤0.01% | 2293 |
|
|
2022
Q3 | $14M | Buy |
204,300
+21,900
| +12% | +$1.3M | ﹤0.01% | 2310 |
|
|
2022
Q2 | $8.25M | Sell |
182,400
-23,500
| -11% | -$1.07M | ﹤0.01% | 2941 |
|
|
2022
Q1 | $10.5M | Sell |
205,900
-31,300
| -13% | -$1.38M | ﹤0.01% | 2872 |
|
|
2021
Q4 | $11.2M | Sell |
237,200
-356,700
| -60% | -$14M | ﹤0.01% | 2881 |
|
|
2021
Q3 | $19.6M | Buy |
593,900
+496,100
| +507% | +$27.9M | ﹤0.01% | 2026 |
|
|
2021
Q2 | $6.18M | Buy |
97,800
+33,500
| +52% | +$1.73M | ﹤0.01% | 3991 |
|
|
2021
Q1 | $2.76M | Buy |
64,300
+18,800
| +41% | +$890K | ﹤0.01% | 5638 |
|
|
2020
Q4 | $2.6M | Buy |
45,500
+22,800
| +100% | +$964K | ﹤0.01% | 4818 |
|
|
2020
Q3 | $685K | Buy |
22,700
+7,200
| +46% | +$215K | ﹤0.01% | 6730 |
|
|
2020
Q2 | $506K | Buy |
15,500
+3,600
| +30% | +$116K | ﹤0.01% | 7050 |
|
|
2020
Q1 | $319K | Sell |
11,900
-7,600
| -39% | -$270K | ﹤0.01% | 7222 |
|
|
2019
Q4 | $597K | Buy |
+19,500
| New | +$540K | ﹤0.01% | 6530 |
|
Other funds holding APLS
Citadel Advisors's APLS Position: Q2 2026 in Review
Citadel Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 38,887 shares — an estimated $1.56M sold.
Citadel Advisors first reported a position in APLS in Q2 2018 and held it in 31 quarters. The position peaked at $82.2M in Q4 2020. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Citadel Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 38,887 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.56M.
- Citadel Advisors first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 31 quarters.
- Citadel Advisors's Apellis Pharmaceuticals position peaked at $82.2M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.